Welcome to our dedicated page for Heska news (Ticker: HSKA), a resource for investors and traders seeking the latest updates and insights on Heska stock.
Heska Corporation (NASDAQ: HSKA) delivers innovative veterinary diagnostic and imaging solutions to advance animal healthcare worldwide. This dedicated news hub provides investors and veterinary professionals with timely updates on Heska's strategic developments, technological breakthroughs, and market positioning.
Key Resources Include: Official announcements of new product releases, financial performance updates, partnership disclosures, and regulatory milestones. Track Heska's progress in diagnostic systems, imaging technologies, and allergy/renal health solutions through verified primary sources.
Stay Informed On: Earnings call details, acquisition activity, research collaborations like the Dalan Animal Health partnership, and enhancements to Heska's Cuattro imaging platform. This centralized repository eliminates the need to monitor multiple channels for critical updates.
Bookmark this page for efficient tracking of Heska's contributions to veterinary medicine and their impact on the animal health sector. Check regularly for unfiltered access to the company's latest advancements in pet care technology.
Heska Corporation (NASDAQ: HSKA) reported a Q1 2022 revenue of $64.8 million, a 7.1% increase year-over-year, with a consolidated gross margin up 290 bps to 45.0%. North America revenue grew slightly by 0.3%, while international revenue surged 18.1%. The company recorded a net loss of $10.0 million and an adjusted EBITDA margin of 11.9%. Key developments include the progress of the Heska Nu.Q® Vet Cancer Screen Test and a focus on point of care diagnostics. Despite the macroeconomic backdrop, Heska expects a full-year growth of at least 13%, with North America consumables projected to grow by 15% or more.
Heska Corporation (NASDAQ: HSKA), a leader in veterinary diagnostics, will host its 2022 Investor Day virtually on May 17, 2022, at 9:00 a.m. MT. Leadership will provide updates on the company's strategic plan for 2023-2027, its position in the global veterinary health market, and new products and services. The event will conclude with a Q&A session. Interested parties can register online to access the webcast, with presentations also available on the company’s investor relations site.
Heska Corporation (NASDAQ: HSKA) will announce its first quarter 2022 financial results on May 9, 2022, before market opening. An earnings call is scheduled for 9 a.m. MT / 11 a.m. ET to discuss the outcomes. The company, specialized in veterinary diagnostics and healthcare solutions, operates in North America and International markets. The earnings call will be accessible via telephonic dial-in and webcast options. A replay will be available shortly after the call.
Heska Corporation (NASDAQ: HSKA) announced its 2022 Annual Meeting of Stockholders, scheduled for May 4, 2022, at 9 a.m. MT / 11 a.m. ET. Stockholders of record as of March 7, 2022, can participate and vote. The meeting will be virtual, and all stockholders are encouraged to vote on proposed matters via proxy as outlined in the proxy materials. A webcast of the meeting will be available, with a replay archived for 90 days on the company's website.
Heska Corporation (NASDAQ: HSKA) has entered an exclusive global supply and licensing agreement with VolitionRx Limited (NYSE AMERICAN: VNRX) to commercialize the Nu.Q® Vet Cancer Screening Test for companion animals. This test aims to provide veterinarians with the ability to screen pets for cancer at the point of care. With an estimated $11 billion market for canine and feline cancer screening, this innovative solution is expected to greatly enhance early detection and treatment for pets, benefiting both healthcare outcomes and pet owners.
Heska Corporation (NASDAQ: HSKA) reported strong financial results for the fourth quarter and full year of 2021, with consolidated revenue rising 28.6% to $253.7 million. Active subscriptions grew by 25%, and significant increases in North America (21.5%) and international (42.2%) sales of POC Lab Consumables were noted. The company expects 2022 revenue growth of 13-17%. Consolidated gross margins improved by 50 bps, reaching 41.7%. Heska remains optimistic about future growth, attributing their success to strategic initiatives and a strong position in the veterinary diagnostics market.
Heska Corporation (NASDAQ: HSKA) will announce its fourth quarter and full year 2021 financial results on February 28, 2022, before market open. An earnings call is scheduled at 9 a.m. MT / 11 a.m. ET to discuss the results. The call can be accessed via phone and will also be webcast live on the company’s investor relations site. A replay will be available from 2 p.m. ET on February 28 through March 14, 2022. Heska manufactures advanced veterinary diagnostic products across North America and internationally.
Heska Corporation (NASDAQ: HSKA) has successfully completed the acquisition of VetZ GmbH, a leader in veterinary practice information management software based in Germany. Announced on November 2, 2021, this acquisition marks a pivotal step in Heska's strategic growth plan. VetZ, known for its integrated software solutions enhancing veterinary workflows and patient care since 1997, is expected to significantly bolster Heska's market position in Europe. Further insights and details regarding the acquisition will be shared during Heska's Q4 and full-year 2021 financial report in February 2022.
Heska Corporation (NASDAQ: HSKA) announced that its President & CEO, Kevin Wilson, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 2:15 p.m. ET. The presentation will be available live for registered attendees and an audio-only version will be accessible to the public. A replay will be available for 90 days after the event. Additionally, Mr. Wilson and the management team will hold one-on-one meetings with investors on the same day. For more details, visit the J.P. Morgan Health Care Conference Website.
Heska Corporation (NASDAQ: HSKA) reported Q3 2021 revenues of $60.2 million, up 6.4% year-over-year. North America revenue rose 9.8% to $37.8 million, driven by 10.1% growth in Point of Care Lab Consumables and 41.1% in Imaging. However, the company faced a net loss of $1.9 million, a 63.6% increase from the prior year. Adjusted EBITDA decreased 34.8% to $5.6 million, with operating margins declining due to $4.5 million in increased expenses. Liquidity remains strong with $222.9 million in cash. Recent acquisitions aim to enhance product offerings.
FAQ
What is the market cap of Heska (HSKA)?
